antifibrinolysin

(redirected from antifibrinolytic)
Also found in: Medical, Wikipedia.

antifibrinolysin

[¦an·tē‚fī·brə′näl·ə·sən]
(biochemistry)
Any substance that inhibits the proteolytic action of fibrinolysin.
References in periodicals archive ?
Conventional Drugs (attenuated androgens, antifibrinolytic agents
If this is insufficient, the patient is given fresh frozen plasma, thrombocyte suspension, and antifibrinolytic drugs [51].
Recent studies have suggested that a steatotic and inflamed liver can cause kidney injury by secreting proinflammatory, profibrogenic, and antifibrinolytic cytokines such as fetuin-A, fibroblast growth factor (FGF)-21, tumor necrosis factor (TNF)-a, transforming growth factor (TGF)-b, and plasminogen activator inhibitor-1.
THE ANTIFIBRINOLYTIC DRUG tranexamic acid appears to significantly improve quality of life for young women who experience heavy menstrual bleeding, new research suggests.
Treatment options for adenomyosis are medical management with agents that reduce bleeding (eg, a combination oral contraceptive [OC], nonsteroidal anti-inflammatory drugs [NSAIDs], the antifibrinolytic tranexamic acid, and, when there is no distortion of the uterine cavity, a levonorgestrel intrauterine device [LNG-IUD]); uterine artery embolization; and hysterectomy.
Treatment is based on the individual evaluation of the patient regarding the necessity for long-term prophylaxis, which can consist of attenuated androgens, antifibrinolytic agents, and plasma-derived C1-INH concentrate (pdC1-INH).
Current status of blood transfusion and antifibrinolytic therapy in orthopedic surgeries.
[38] Management of major bleeds revolves around haemodialysis, administering an antifibrinolytic agent and prothrombotic clotting factors.
Antifibrinolytic agents have been associated with decreased blood loss in various clinical applications.
As a synthetic antifibrinolytic agent, it can competitively inhibit the activation of plasminogen and noncompetitively inhibit the plasmin activity at high concentrations.[6] Consequently, TXA can reduce the blood loss by decreasing the conversion of plasminogen into plasmin, an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins including procoagulant factors 5 and 8.[7] TXA has been proven to be effective in reducing TBL and transfusions after TKA by different methods without risk of complications.[6],[8],[9],[10],[11] The most commonly reported administration methods included intravenous (IV) and topical administration.[12] Moreover, there is no difference in efficiency and safety between IV or topical administration.
Current treatment modalities for FXI deficiency include administration of FFP, replacement therapy with FXI concentrates, antifibrinolytic medication support, fibrin glue application, and although less common, desmopressin treatment.
Antifibrinolytic agents like tranexamic acid, has been used in our setup in cardiac surgery to reduce blood loss and need for transfusions.